Cargando…

Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans

OBJECTIVE: To evaluate the potential for pharmacokinetic interaction and the safety and tolerability when ubrogepant and sumatriptan are coadministered in a Phase 1 study in healthy participants, and to inform the safety and tolerability of ubrogepant alone and in combination with triptans in Phase...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jakate, Abhijeet, Boinpally, Ramesh, Butler, Matthew, Lu, Kaifeng, McGeeney, Danielle, Periclou, Antonia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Submissions
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7496299/ https://www.ncbi.nlm.nih.gov/pubmed/32573795 http://dx.doi.org/10.1111/head.13862

Ejemplares similares

Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene‒related peptide‐targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug–drug interaction study
por: Jakate, Abhijeet, et al.
Publicado: (2021)

Single Therapeutic and Supratherapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial
por: Jakate, Abhijeet, et al.
Publicado: (2019)

Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension Trial
por: Ailani, Jessica, et al.
Publicado: (2020)

Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Single‐Dose Pharmacokinetics and Safety of Atogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Time course of efficacy of ubrogepant for the acute treatment of migraine: Clinical implications
por: Goadsby, Peter J, et al.
Publicado: (2020)

Ubrogepant, an Acute Treatment for Migraine, Improved Patient‐Reported Functional Disability and Satisfaction in 2 Single‐Attack Phase 3 Randomized Trials, ACHIEVE I and II
por: Dodick, David W., et al.
Publicado: (2020)

Correction to: Ubrogepant: First Approval
por: Scott, Lesley J.
Publicado: (2020)

Improved Pharmacokinetics of Sumatriptan With Breath Powered™ Nasal Delivery of Sumatriptan Powder
por: Obaidi, Mohammad, et al.
Publicado: (2013)

Mechanistic Investigations Support Liver Safety of Ubrogepant
por: Smith, Brenda, et al.
Publicado: (2020)

Safety and tolerability of ubrogepant following intermittent, high-frequency dosing: Randomized, placebo-controlled trial in healthy adults
por: Goadsby, Peter J, et al.
Publicado: (2019)

Ubrogepant to Treat Acute Migraine in Adults
por: Edinoff, Amber N., et al.
Publicado: (2021)

Ubrogepant Is Not Associated With Clinically Meaningful Elevations of Alanine Aminotransferase in Healthy Adult Males
por: Ankrom, Wendy, et al.
Publicado: (2020)

A Single Supratherapeutic Dose of Atogepant Does Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized, Single‐Dose, Phase 1 Crossover Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

An Open‐Label Study to Evaluate the Effect of Eluxadoline on the Single‐Dose Pharmacokinetics of Midazolam in Healthy Participants
por: Boinpally, Ramesh, et al.
Publicado: (2022)

Ubrogepant in the Acute Management of Migraine: A Narrative Review
por: Chiang, Chia-Chun, et al.
Publicado: (2021)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

A Comprehensive Review of the Mechanism, Efficacy, Safety, and Tolerability of Ubrogepant in the Treatment of Migraine
por: Dighriri, Ibrahim M, et al.
Publicado: (2023)

Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
por: Lipton, Richard B., et al.
Publicado: (2022)

Ubrogepant does not induce latent sensitization in a preclinical model of medication overuse headache
por: Navratilova, Edita, et al.
Publicado: (2020)

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain
por: Lipton, Richard B., et al.
Publicado: (2022)

AVP-825 Breath-Powered Intranasal Delivery System Containing 22 mg Sumatriptan Powder vs 100 mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
por: Tepper, Stewart J, et al.
Publicado: (2015)

Triptans and vascular comorbidity in persons over fifty: Findings from a nationwide insurance database – A cohort study
por: Zebenholzer, Karin, et al.
Publicado: (2022)

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials
por: Blumenfeld, Andrew M., et al.
Publicado: (2021)

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis
por: Zhang, Zizhen, et al.
Publicado: (2021)

Relative efficacy of lasmiditan versus rimegepant and ubrogepant as acute treatments for migraine: network meta-analysis findings
por: Polavieja, Pepa, et al.
Publicado: (2022)

A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
por: Cady, Roger K, et al.
Publicado: (2015)

Ubrogepant for the Acute Treatment of Migraine: Pooled Efficacy, Safety, and Tolerability From the ACHIEVE I and ACHIEVE II Phase 3 Randomized Trials
por: Hutchinson, Susan, et al.
Publicado: (2021)

Post Hoc Subanalysis of Two Randomized, Controlled Phase 3 Trials Evaluating Diclofenac Potassium for Oral Solution: Impact of Migraine‐Associated Nausea and Prior Triptan Use on Efficacy
por: Lipton, Richard B., et al.
Publicado: (2017)

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
por: Johnston, Karissa M, et al.
Publicado: (2022)

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
por: Manack Adams, Aubrey, et al.
Publicado: (2023)

Making Better Dose Decisions: Using Exposure‐Response Modeling to Integrate Efficacy Outcome of Two Phase IIb Clinical Trials of Ubrogepant for Migraine Treatment
por: Li, Chi‐Chung, et al.
Publicado: (2020)

A focus on pleasure? Desire and disgust in group work with young men
por: McGeeney, Ester
Publicado: (2015)

Valsalva-induced cluster headache
por: McGeeney, B. E.
Publicado: (2006)

Evaluation of the Pharmacokinetic Interaction and Safety of Atogepant Co-Administered with Acetaminophen or Naproxen in Healthy Participants: A Randomized Trial
por: Boinpally, Ramesh, et al.
Publicado: (2021)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Tolerability and safety of galcanezumab in patients with chronic cluster headache with up to 15 months of galcanezumab treatment
por: Láinez, Miguel J. A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_65mjql1r9p2745hsls0j513vec